View in EDS HTML Full Text PDF Full Text

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.

Saved in:
Bibliographic Details
Title: Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.
Authors: Mansfield AS; Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA. Mansfield.aaron@mayo.edu., Wei Z; ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA, USA., Mehra R; Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, USA., Shaw AT; Massachusetts General Hospital, Boston, MA, USA., Lieu CH; University of Colorado Cancer Center, Aurora, CO, USA., Forde PM; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA., Drilon AE; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA., Mitchell EP; Thomas Jefferson University Hospital, Philadelphia, PA, USA., Wright JJ; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Takebe N; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Sharon E; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Hovelson D; Strata Oncology, Inc, Ann Arbor, MI, USA., Tomlins S; Strata Oncology, Inc, Ann Arbor, MI, USA., Zeng J; Caris Life Sciences, Irving, TX, USA., Poorman K; Caris Life Sciences, Irving, TX, USA., Malik N; Tempus, Chicago, IL, USA., Gray RJ; ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA, USA., Li S; ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA, USA., McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Patton D; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD, USA., Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Hamilton SR; City of Hope, Duarte, CA, USA., Conley BA; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Arteaga CL; Simmons Cancer Center, University of Texas Southwestern, Dallas, TX, USA., Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA, USA., Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Flaherty KT; Massachusetts General Hospital, Boston, MA, USA.
Source: NPJ precision oncology [NPJ Precis Oncol] 2022 Mar 01; Vol. 6 (1), pp. 13. Date of Electronic Publication: 2022 Mar 01.
Publication Type: Journal Article
Journal Info: Publisher: Springer Nature Country of Publication: England NLM ID: 101708166 Publication Model: Electronic Cited Medium: Print ISSN: 2397-768X (Print) Linking ISSN: 2397768X NLM ISO Abbreviation: NPJ Precis Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35233056
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Mansfield+AS%22">Mansfield AS</searchLink>; Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA. Mansfield.aaron@mayo.edu.<br /><searchLink fieldCode="AU" term="%22Wei+Z%22">Wei Z</searchLink>; ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Mehra+R%22">Mehra R</searchLink>; Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22Shaw+AT%22">Shaw AT</searchLink>; Massachusetts General Hospital, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Lieu+CH%22">Lieu CH</searchLink>; University of Colorado Cancer Center, Aurora, CO, USA.<br /><searchLink fieldCode="AU" term="%22Forde+PM%22">Forde PM</searchLink>; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22Drilon+AE%22">Drilon AE</searchLink>; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Mitchell+EP%22">Mitchell EP</searchLink>; Thomas Jefferson University Hospital, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Wright+JJ%22">Wright JJ</searchLink>; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Takebe+N%22">Takebe N</searchLink>; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Sharon+E%22">Sharon E</searchLink>; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Hovelson+D%22">Hovelson D</searchLink>; Strata Oncology, Inc, Ann Arbor, MI, USA.<br /><searchLink fieldCode="AU" term="%22Tomlins+S%22">Tomlins S</searchLink>; Strata Oncology, Inc, Ann Arbor, MI, USA.<br /><searchLink fieldCode="AU" term="%22Zeng+J%22">Zeng J</searchLink>; Caris Life Sciences, Irving, TX, USA.<br /><searchLink fieldCode="AU" term="%22Poorman+K%22">Poorman K</searchLink>; Caris Life Sciences, Irving, TX, USA.<br /><searchLink fieldCode="AU" term="%22Malik+N%22">Malik N</searchLink>; Tempus, Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Gray+RJ%22">Gray RJ</searchLink>; ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Li+S%22">Li S</searchLink>; ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22McShane+LM%22">McShane LM</searchLink>; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Rubinstein+LV%22">Rubinstein LV</searchLink>; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Patton+D%22">Patton D</searchLink>; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Williams+PM%22">Williams PM</searchLink>; Frederick National Laboratory for Cancer Research, Frederick, MD, USA.<br /><searchLink fieldCode="AU" term="%22Hamilton+SR%22">Hamilton SR</searchLink>; City of Hope, Duarte, CA, USA.<br /><searchLink fieldCode="AU" term="%22Conley+BA%22">Conley BA</searchLink>; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Arteaga+CL%22">Arteaga CL</searchLink>; Simmons Cancer Center, University of Texas Southwestern, Dallas, TX, USA.<br /><searchLink fieldCode="AU" term="%22Harris+LN%22">Harris LN</searchLink>; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22O'Dwyer+PJ%22">O'Dwyer PJ</searchLink>; University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Chen+AP%22">Chen AP</searchLink>; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Flaherty+KT%22">Flaherty KT</searchLink>; Massachusetts General Hospital, Boston, MA, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101708166%22">NPJ precision oncology</searchLink> [NPJ Precis Oncol] 2022 Mar 01; Vol. 6 (1), pp. 13. <i>Date of Electronic Publication: </i>2022 Mar 01.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Nature%22">Springer Nature </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101708166 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Print <i>ISSN: </i>2397-768X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222397768X%22">2397768X </searchLink><i>NLM ISO Abbreviation: </i>NPJ Precis Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35233056
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41698-022-00256-w
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 13
    Titles:
      – TitleFull: Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Mansfield AS
      – PersonEntity:
          Name:
            NameFull: Wei Z
      – PersonEntity:
          Name:
            NameFull: Mehra R
      – PersonEntity:
          Name:
            NameFull: Shaw AT
      – PersonEntity:
          Name:
            NameFull: Lieu CH
      – PersonEntity:
          Name:
            NameFull: Forde PM
      – PersonEntity:
          Name:
            NameFull: Drilon AE
      – PersonEntity:
          Name:
            NameFull: Mitchell EP
      – PersonEntity:
          Name:
            NameFull: Wright JJ
      – PersonEntity:
          Name:
            NameFull: Takebe N
      – PersonEntity:
          Name:
            NameFull: Sharon E
      – PersonEntity:
          Name:
            NameFull: Hovelson D
      – PersonEntity:
          Name:
            NameFull: Tomlins S
      – PersonEntity:
          Name:
            NameFull: Zeng J
      – PersonEntity:
          Name:
            NameFull: Poorman K
      – PersonEntity:
          Name:
            NameFull: Malik N
      – PersonEntity:
          Name:
            NameFull: Gray RJ
      – PersonEntity:
          Name:
            NameFull: Li S
      – PersonEntity:
          Name:
            NameFull: McShane LM
      – PersonEntity:
          Name:
            NameFull: Rubinstein LV
      – PersonEntity:
          Name:
            NameFull: Patton D
      – PersonEntity:
          Name:
            NameFull: Williams PM
      – PersonEntity:
          Name:
            NameFull: Hamilton SR
      – PersonEntity:
          Name:
            NameFull: Conley BA
      – PersonEntity:
          Name:
            NameFull: Arteaga CL
      – PersonEntity:
          Name:
            NameFull: Harris LN
      – PersonEntity:
          Name:
            NameFull: O'Dwyer PJ
      – PersonEntity:
          Name:
            NameFull: Chen AP
      – PersonEntity:
          Name:
            NameFull: Flaherty KT
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: 2022 Mar 01
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 2397-768X
          Numbering:
            – Type: volume
              Value: 6
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: NPJ precision oncology
              Type: main
ResultId 1